| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1425514 | Journal of Controlled Release | 2010 | 7 Pages |
An alternative vaccine delivery system for needle injections is the Bioneedle. Hepatitis B surface antigen (HBsAg) was formulated with Bioneedles. Three formulations were used: plain antigen, HBsAg adjuvated with aluminum hydroxide and HBsAg with LPS-derived lpxL1. Bioneedles with HBsAg-lpxL1 were the most stable and the most immunogenic formulations. The conventional liquid alum adjuvated vaccine lost 40% of its antigenicity after 1 week at 50 °C whereas the HBsAg-lpxL1 Bioneedles showed no significant decrease after 3 weeks at 50 °C. In vivo studies revealed that the HBsAg-lpxL1 Bioneedle formulations induced comparable IgG titers as conventional liquid formulations after 2 immunizations, but higher IgG2a titers were found already after 1 immunization. The in vivo and in vitro studies showed that the Bioneedle is an attractive alternative for needle injections of HBsAg vaccines.
Graphical abstractHepatitis B formulated with Bioneedles is an attractive alternative for conventional needle injections.Figure optionsDownload full-size imageDownload as PowerPoint slide
